Connect your agent to akta.pro and build company lists like this across sectors and geos.
The top 10 most active VC and CVC investors in US Healthcare, ranked by distinct funding events observed in akta.pro News Signals over the Jan 1–Sep 26, 2026 window, with deal count, lead posture, round capital and observed focus for each. Data compiled Sep 26, 2026.
Editorial list Coverage: US Filter: VC + CVC investors only Ranked by: Deal count Source: akta.pro News Signals Updated: Sep 26, 2026
Investors tracked 10 US Healthcare · ranked by deal count Disclosed funding — no round values disclosed Top-ranked investor 5th Century Partners 1 deal · value not disclosed Search VC type Observed focus Sort by Top 10 active VC investors Distinct events · normalized investor names · ranked top 10 VCs| # | Investor | Deals | Round capital* | Type | Observed focus | Investments in window | Latest deal | News sources |
|---|---|---|---|---|---|---|---|---|
| 01 | 5th Century Partners Chicago, IL | 1 | — disclosed rounds | PE | Outpatient Physical Therapy Services | ION PT Network — Sep 25, 2026 | 1 article · 1 publisher | |
| 02 | Relevance Ventures Nashville, TN | 1 | — disclosed rounds | VC | Gastrointestinal Endoscopy Device | Aqua Medical — Sep 25, 2026 | 1 article · 1 publisher | |
| 03 | NMS Capital New York, NY | 1 | — disclosed rounds | PE | Surgical Equipment Services (MRO) | Asurgence Medical (ENDOCORP + Medical Optics) — Sep 17, 2026 | 1 article · 1 publisher | |
| 04 | Kohlberg & Company Mount Kisco, NY | 1 | — disclosed rounds | PE | Medtech Contract Manufacturing | Cadence Inc. — Aug 28, 2026 | 1 article · 1 publisher | |
| 05 | WindRose Health Investors New York, NY | 1 | — disclosed rounds | PE | Clinical Trial Technology | Verified Clinical Trials — Aug 6, 2026 | 1 article · 1 publisher | |
| 06 | HPS Investment Partners New York, NY | 1 | — disclosed rounds | PE | Behavioral Health | Discovery Behavioral Health — Jun 2, 2026 | 1 article · 1 publisher | |
| 07 | Align Capital Partners Dallas, TX | 1 | — disclosed rounds | PE | Diagnostic Imaging | Heritage Imaging — May 28, 2026 | 1 article · 1 publisher | |
| 08 | Havencrest Capital Management Dallas, TX | 1 | — disclosed rounds | PE | Anesthesia & Dental Services | OFFOR Health — Apr 9, 2026 | 1 article · 1 publisher | |
| 09 | Patient Square Capital Menlo Park, CA | 1 | — disclosed rounds | PE | Complex Care Management Clinical Research (CRO) | Paradigm — Feb 16, 2026 | 1 article · 1 publisher | |
| 10 | Amulet Capital Partners New York, NY | 1 | — disclosed rounds | PE | Fertility Services | US Fertility — Sep 14, 2026 | 1 article · 1 publisher |
Healthcare, as scoped for this run, covers hospital and specialty health systems, physician and specialist practice groups, dental service organizations, behavioral and autism/ABA therapy providers, home health and hospice operators, elder and in-home care, diagnostic imaging and clinical laboratory services, clinical research organizations, medtech contract manufacturing, and digital health platforms.
This scope is distinct from adjacent categories such as pure biotech and pharmaceutical drug development, which remain dominated by venture and public capital markets rather than private equity buyout activity, and from veterinary care and public health or government health programs, which fall outside private-equity healthcare-services investing.
A notable structural feature of this window is that control-oriented buyouts and recapitalizations of care-delivery platforms, such as physician practices, home health, behavioral health, and dental groups, outnumbered pure minority growth checks among named transactions, and disclosed pricing was uncommon, appearing in only a handful of the identified deals.
This run covers privately held, US-headquartered healthcare-services and medtech companies where a private equity or growth-equity sponsor made a majority, growth, buyout, or take-private investment during the retrieval window (2026-01-01 to 2026-09-26), identified via explicit deal-language headlines (private equity, buyout, recapitalization, growth equity, majority stake, portfolio company); pure biotech/pharma financings, bank- or asset-manager-led-only transactions, and non-US targets were excluded, and reliance on headline-level deal language means the sample favors well-covered transactions rather than the full universe of PE healthcare activity.
Companies are tagged against standard industry codes and against akta.pro’s internal taxonomy, so the same set can be rebuilt by code, by segment, or by a combination of both.
NAICS and SIC codes are standard, cross-industry federal classification systems used for cross-referencing against public filings and procurement records. akta.pro’s internal taxonomy is independent of them, so a company may carry an internal segment without a matching NAICS or SIC registration.